<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820260</url>
  </required_header>
  <id_info>
    <org_study_id>LP0105-1012</org_study_id>
    <nct_id>NCT01820260</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis</brief_title>
  <official_title>Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily&#xD;
      treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in&#xD;
      different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle&#xD;
      gel&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 was an open-label, dose escalation. Part 2 was a randomised, double-blind, parallel group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking only for Part 2</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: To Identify the Maximum Tolerated Dose (MTD) Levels After Once Daily Treatment for 2 or 3 Days</measure>
    <time_frame>8 days after initial treatment</time_frame>
    <description>Dose tolerability was measures looking at the composite score of Local Skin Responses (LSR). The MTD was defined as the highest dose level with less than 4 subjects out of 12 experiencing dose limiting toxicity (DLT).&#xD;
DLT was defined as one or more of the following three local skin LSRs:&#xD;
Crusting Grade 4&#xD;
Erosion/Ulceration Grade 4&#xD;
Vesiculation/Pustulation Grade 4 or two or more of the following five LSRs:&#xD;
Erythema Grade 4&#xD;
Crusting Grade 3&#xD;
Swelling Grade 4&#xD;
Erosion/Ulceration Grade 3&#xD;
Vesiculation/Pustulation Grade 3&#xD;
The grading is a scale of 1 to 4 (highest grade).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Subjects With Complete Clearance of AKs</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of subjects with complete clearance of Actinic Keratosis lesions (AKs) at week 8 after 2 or 3 consecutive days of treatment with ingenol mebutate gel on the full face, full balding scalp or approximately 250 cmÂ² on the chest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Reduction in AK Count</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <description>Reduction in actinic keratosis lesion count from baseline to week 8 (percentage, adjusted for anatomical location and pooled site)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Subjects With Partial Clearance of AKs</measure>
    <time_frame>Week 8</time_frame>
    <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.005%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.018% for 3 days treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.018% for 2 days treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.027% for 3 days treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.027% for 2 days treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo for 3 days treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo for 2 days treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.008%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.012%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.027%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.04%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: Ingenol mebutate gel 0.06%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.018%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: Ingenol mebutate gel 0.04%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose escalation, 2 days treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol mebutate gel</intervention_name>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.005%</arm_group_label>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.008%</arm_group_label>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.012%</arm_group_label>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.018%</arm_group_label>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.027%</arm_group_label>
    <arm_group_label>Part 1A: Ingenol mebutate gel 0.04%</arm_group_label>
    <arm_group_label>Part 1B: Ingenol mebutate gel 0.04%</arm_group_label>
    <arm_group_label>Part 1B: Ingenol mebutate gel 0.06%</arm_group_label>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.018% for 2 days treatment</arm_group_label>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.018% for 3 days treatment</arm_group_label>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.027% for 2 days treatment</arm_group_label>
    <arm_group_label>Part 2: Ingenol mebutate gel 0.027% for 3 days treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Part 2: Placebo for 2 days treatment</arm_group_label>
    <arm_group_label>Part 2: Placebo for 3 days treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be competent to understand the nature of the trial and provide informed&#xD;
             consent&#xD;
&#xD;
          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the face&#xD;
             Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on either&#xD;
             the face, the balding scalp (the balding part of the scalp should be at least 25 cm2)&#xD;
             or a contiguous area of approximately 250 cm2 on the chest&#xD;
&#xD;
          -  Subject at least 18 years of age&#xD;
&#xD;
          -  Female subjects must be of either:&#xD;
&#xD;
               1. Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical&#xD;
                  history of sterility (e.g. the subject is without a uterus) or,&#xD;
&#xD;
               2. Childbearing potential, provided there is a confirmed negative urine pregnancy&#xD;
                  test prior to trial treatment, to rule out pregnancy&#xD;
&#xD;
          -  Female subjects of childbearing potential1 must be willing to use effective&#xD;
             contraception at trial entry and until completion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Location of the treatment area (full face, full balding scalp or chest)&#xD;
&#xD;
               -  within 5 cm of an incompletely healed wound,&#xD;
&#xD;
               -  within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma&#xD;
                  (SCC&#xD;
&#xD;
          -  Prior treatment with ingenol mebutate gel within the treatment area&#xD;
&#xD;
          -  Lesions in the treatment areas that have:&#xD;
&#xD;
               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous&#xD;
                  horns) and/or,&#xD;
&#xD;
               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous&#xD;
                  occasions&#xD;
&#xD;
          -  History or evidence of skin conditions other than the trial indication that would&#xD;
             interfere with the evaluation of the trial medication (e.g., eczema, unstable&#xD;
             psoriasis, xeroderma pigmentosum)&#xD;
&#xD;
          -  Use of cosmetic or therapeutic products and procedures which could interfere with the&#xD;
             assessments of the treatment areas.&#xD;
&#xD;
          -  Clinical diagnosis/history or evidence of any medical condition that would expose a&#xD;
             subject to an undue risk of a significant AE or interfere with assessments of safety&#xD;
             and efficacy during the course of the trial, as determined by the investigator's&#xD;
             clinical judgment&#xD;
&#xD;
          -  Any abnormal laboratory tests that are medically significant and would impact the&#xD;
             safety of the subjects or the interpretation of the trial results, as determined by&#xD;
             the investigator's judgment&#xD;
&#xD;
          -  Anticipated need for hospitalisation or out-patient surgery during the first 15 days&#xD;
             after the first trial medication application. Note that cosmetic/therapeutic&#xD;
             procedures are not excluded if they fall outside of the criteria detailed in&#xD;
             Prohibited Therapies or Medications&#xD;
&#xD;
          -  Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel&#xD;
&#xD;
          -  Presence of acute sunburn within the treatment areas&#xD;
&#xD;
          -  Current enrolment or participation in an investigational clinical trial within 30 days&#xD;
             of entry into this trial.&#xD;
&#xD;
          -  Subjects previously assigned to treatment in Part 1 or rand&#xD;
&#xD;
          -  Female subjects who are breastfeeding.&#xD;
&#xD;
          -  In the opinion of the investigator, the subject is unlikely to comply with the&#xD;
             Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. William Hanke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser &amp; Skin Surgery Center of Indiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Inidana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <results_first_submitted>October 30, 2018</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <disposition_first_submitted>July 2, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 27, 2015</disposition_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part 1: There was 1 of the 82 subjects who withdrew before receiving any treatment but after collection of baseline characteristics. 81 subjects received treatment and all completed the trial.&#xD;
Part 2: There were 2 of the 315 randomized subjects who withdrew consent prior to any baseline characteristics being recorded (therefore they received no treatment) and are excluded from the total number of participants, full analysis set and safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1A: Ingenol Mebutate Gel 0.005%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>Part 1A: Ingenol Mebutate Gel 0.008%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P3">
          <title>Part 1A: Ingenol Mebutate Gel 0.012%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P4">
          <title>Part 1A: Ingenol Mebutate Gel 0.018%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P5">
          <title>Part 1A: Ingenol Mebutate Gel 0.027%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P6">
          <title>Part 1A: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P7">
          <title>Part 1B: Ingenol Mebutate Gel 0.06%</title>
          <description>Administration on full face, once daily for 2 consecutive days</description>
        </group>
        <group group_id="P8">
          <title>Part 1B: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily for 2 consecutive days</description>
        </group>
        <group group_id="P9">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 2 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
        <group group_id="P10">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 3 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P11">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 2 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
        <group group_id="P12">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 3 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
        <group group_id="P13">
          <title>Part 2: Vehicle Gel (Placebo) for 2 Days</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
        <group group_id="P14">
          <title>Part 2: Vehicle Gel (Placebo) for 3 Days</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1 (Part 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject withdrew after randomization before treatment assignment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 (Part 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="64"/>
                <participants group_id="P10" count="62"/>
                <participants group_id="P11" count="61"/>
                <participants group_id="P12" count="64"/>
                <participants group_id="P13" count="31"/>
                <participants group_id="P14" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="64"/>
                <participants group_id="P10" count="61"/>
                <participants group_id="P11" count="61"/>
                <participants group_id="P12" count="64"/>
                <participants group_id="P13" count="31"/>
                <participants group_id="P14" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For the Safety Analysis set for Part 1 the was 1 subject out of 12 not included in the Part 1B Ingenol Mebute Gel 0.06%. This subject discontinued before receiving any trial medication. Therefore, there are only 11 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1A: Ingenol Mebutate Gel 0.005%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Part 1A: Ingenol Mebutate Gel 0.008%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Part 1A: Ingenol Mebutate Gel 0.012%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B4">
          <title>Part 1A: Ingenol Mebutate Gel 0.018%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B5">
          <title>Part 1A: Ingenol Mebutate Gel 0.027%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B6">
          <title>Part 1A: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily for 3 days</description>
        </group>
        <group group_id="B7">
          <title>Part 1B: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily for 2 days</description>
        </group>
        <group group_id="B8">
          <title>Part 1B: Ingenol Mebutate Gel 0.06%</title>
          <description>Administration on full face, once daily for 2 days</description>
        </group>
        <group group_id="B9">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 3 Days Treatment</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
        </group>
        <group group_id="B10">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 3 Days Treatment</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
        </group>
        <group group_id="B11">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 2 Days Treatment</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
        </group>
        <group group_id="B12">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 2 Days Treatment</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
        </group>
        <group group_id="B13">
          <title>Part 2: Vehicle Gel (Placebo)for 2 Days Treatment</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Vehicle gel (placebo)</description>
        </group>
        <group group_id="B14">
          <title>Part 2: Vehicle Gel (Placebo) for 3 Days Treatment</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Vehicle gel (placebo)</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="11"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="62"/>
            <count group_id="B10" value="64"/>
            <count group_id="B11" value="64"/>
            <count group_id="B12" value="61"/>
            <count group_id="B13" value="31"/>
            <count group_id="B14" value="31"/>
            <count group_id="B15" value="395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" lower_limit="72" upper_limit="78"/>
                    <measurement group_id="B2" value="69.6" lower_limit="51" upper_limit="85"/>
                    <measurement group_id="B3" value="68.7" lower_limit="48" upper_limit="81"/>
                    <measurement group_id="B4" value="67.4" lower_limit="41" upper_limit="83"/>
                    <measurement group_id="B5" value="69.7" lower_limit="56" upper_limit="84"/>
                    <measurement group_id="B6" value="68.0" lower_limit="47" upper_limit="85"/>
                    <measurement group_id="B7" value="67.5" lower_limit="57" upper_limit="83"/>
                    <measurement group_id="B8" value="71.7" lower_limit="52" upper_limit="92"/>
                    <measurement group_id="B9" value="68.0" lower_limit="46" upper_limit="88"/>
                    <measurement group_id="B10" value="66.3" lower_limit="49" upper_limit="88"/>
                    <measurement group_id="B11" value="66.9" lower_limit="47" upper_limit="91"/>
                    <measurement group_id="B12" value="66.1" lower_limit="50" upper_limit="84"/>
                    <measurement group_id="B13" value="68.4" lower_limit="48" upper_limit="83"/>
                    <measurement group_id="B14" value="69.0" lower_limit="43" upper_limit="87"/>
                    <measurement group_id="B15" value="68.0" lower_limit="41" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="15"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="42"/>
                    <measurement group_id="B10" value="49"/>
                    <measurement group_id="B11" value="56"/>
                    <measurement group_id="B12" value="46"/>
                    <measurement group_id="B13" value="28"/>
                    <measurement group_id="B14" value="26"/>
                    <measurement group_id="B15" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="62"/>
                    <measurement group_id="B10" value="64"/>
                    <measurement group_id="B11" value="64"/>
                    <measurement group_id="B12" value="61"/>
                    <measurement group_id="B13" value="31"/>
                    <measurement group_id="B14" value="31"/>
                    <measurement group_id="B15" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: To Identify the Maximum Tolerated Dose (MTD) Levels After Once Daily Treatment for 2 or 3 Days</title>
        <description>Dose tolerability was measures looking at the composite score of Local Skin Responses (LSR). The MTD was defined as the highest dose level with less than 4 subjects out of 12 experiencing dose limiting toxicity (DLT).&#xD;
DLT was defined as one or more of the following three local skin LSRs:&#xD;
Crusting Grade 4&#xD;
Erosion/Ulceration Grade 4&#xD;
Vesiculation/Pustulation Grade 4 or two or more of the following five LSRs:&#xD;
Erythema Grade 4&#xD;
Crusting Grade 3&#xD;
Swelling Grade 4&#xD;
Erosion/Ulceration Grade 3&#xD;
Vesiculation/Pustulation Grade 3&#xD;
The grading is a scale of 1 to 4 (highest grade).</description>
        <time_frame>8 days after initial treatment</time_frame>
        <population>The composite (sum) score was obtained by summing the 6 individual LSRs</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1A: Ingenol Mebutate Gel 0.005%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Part 1A: Ingenol Mebutate Gel 0.008%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Part 1A: Ingenol Mebutate Gel 0.012%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>Part 1A: Ingenol Mebutate Gel 0.018%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>Part 1A: Ingenol Mebutate Gel 0.027%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>Part 1A: Ingenol Mebutate Gel 0.04%</title>
            <description>Administration on full face, once daily for 3 consecutive days</description>
          </group>
          <group group_id="O7">
            <title>Part 1B: Ingenol Mebutate Gel 0.04%</title>
            <description>Administration on full face, once daily for 2 consecutive days</description>
          </group>
          <group group_id="O8">
            <title>Part 1B: Ingenol Mebutate Gel 0.06%</title>
            <description>Administration on full face, once daily for 2 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: To Identify the Maximum Tolerated Dose (MTD) Levels After Once Daily Treatment for 2 or 3 Days</title>
          <description>Dose tolerability was measures looking at the composite score of Local Skin Responses (LSR). The MTD was defined as the highest dose level with less than 4 subjects out of 12 experiencing dose limiting toxicity (DLT).&#xD;
DLT was defined as one or more of the following three local skin LSRs:&#xD;
Crusting Grade 4&#xD;
Erosion/Ulceration Grade 4&#xD;
Vesiculation/Pustulation Grade 4 or two or more of the following five LSRs:&#xD;
Erythema Grade 4&#xD;
Crusting Grade 3&#xD;
Swelling Grade 4&#xD;
Erosion/Ulceration Grade 3&#xD;
Vesiculation/Pustulation Grade 3&#xD;
The grading is a scale of 1 to 4 (highest grade).</description>
          <population>The composite (sum) score was obtained by summing the 6 individual LSRs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Subjects With Complete Clearance of AKs</title>
        <description>Number of subjects with complete clearance of Actinic Keratosis lesions (AKs) at week 8 after 2 or 3 consecutive days of treatment with ingenol mebutate gel on the full face, full balding scalp or approximately 250 cmÂ² on the chest</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel 0.018% for 3 Days</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O2">
            <title>Ingenol Mebutate Gel 0.018% for 2 Days</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O3">
            <title>Ingenol Mebutate Gel 0.027% for 3 Days</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O4">
            <title>Ingenol Mebutate Gel 0.027% for 2 Days</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel (Placebo) for 3 Days</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Vehicle gel (placebo)</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Gel (Placebo) for 2 Days</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Vehicle gel (placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Subjects With Complete Clearance of AKs</title>
          <description>Number of subjects with complete clearance of Actinic Keratosis lesions (AKs) at week 8 after 2 or 3 consecutive days of treatment with ingenol mebutate gel on the full face, full balding scalp or approximately 250 cmÂ² on the chest</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Complete clearance of AKs at Week 8 was to be analysed by log binomial regression with factors treatment group, anatomical location (face/chest or scalp) and analysis site. Due to the low numbers of subjects obtaining complete clearance in the vehicle groups,the proposed model did not converge and Fisher's exact test was used instead to compare active treatments with the respective vehicle arm.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>To account for multiple testing, the 4 pairwise tests with corresponding vehicle group were performed using Bonferroni method testing at a 1.25% significance level, securing that the overall significance level did not exceed 5%</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>See comment in analysis 1</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0037</p_value>
            <p_value_desc>see comments in analysis 1</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>See comments in analysis 1</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0171</p_value>
            <p_value_desc>See comments in analysis 1</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Reduction in AK Count</title>
        <description>Reduction in actinic keratosis lesion count from baseline to week 8 (percentage, adjusted for anatomical location and pooled site)</description>
        <time_frame>From baseline to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel 0.018% for 3 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O2">
            <title>Ingenol Mebutate Gel 0.018% for 2 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O3">
            <title>Ingenol Mebutate Gel 0.027% for 3 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O4">
            <title>Ingenol Mebutate Gel 0.027% for 2 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel (Placebo) for 3 Days Treatment</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Vehicle gel (placebo)</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Gel (Placebo)for 2 Days Treatment</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Vehicle gel (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Reduction in AK Count</title>
          <description>Reduction in actinic keratosis lesion count from baseline to week 8 (percentage, adjusted for anatomical location and pooled site)</description>
          <units>Percentage reduction</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="66.4" upper_limit="79.1"/>
                    <measurement group_id="O2" value="70.5" lower_limit="62.8" upper_limit="76.6"/>
                    <measurement group_id="O3" value="82.9" lower_limit="77.6" upper_limit="86.9"/>
                    <measurement group_id="O4" value="67.7" lower_limit="59.1" upper_limit="74.5"/>
                    <measurement group_id="O5" value="4.3" lower_limit="-28.1" upper_limit="28.5"/>
                    <measurement group_id="O6" value="15.7" lower_limit="-12.9" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>To account for multiple testing among the secondary endpoints, a hierarchical order of testing was determined, where the following evaluation was done separately for each of the four active groups: Provided the primary endpoint was significant at a 1.25% level, the comparison to vehicle in terms of reduction in AK count from baseline to week 8 was tested at a 1.25% level. Provided this test was significant, the second secondary endpoint,partial clearance, was tested(vs. vehicle) at a 1.25% level</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>z-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>See comment in analysis 1</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>z-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>See comment analysis 1</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>z-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>See comment in analysis 1</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>z-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Subjects With Partial Clearance of AKs</title>
        <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel 0.018% for 3 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O2">
            <title>Ingenol Mebutate Gel 0.018% for 2 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.018%</description>
          </group>
          <group group_id="O3">
            <title>Ingenol Mebutate Gel 0.027% for 3 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O4">
            <title>Ingenol Mebutate Gel 0.027% for 2 Days Treatment</title>
            <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Ingenol mebutate gel 0.027%</description>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel (Placebo) for 3 Days Treatment</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days&#xD;
Vehicle gel (placebo)</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Gel (Placebo)for 2 Days Treatment</title>
            <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days&#xD;
Vehicle gel (placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Subjects With Partial Clearance of AKs</title>
          <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="76.6"/>
                    <measurement group_id="O4" value="52.5"/>
                    <measurement group_id="O5" value="6.5"/>
                    <measurement group_id="O6" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of partial clearance of AK's at Week 8 was done in the same way as for the primary outcome (endpoint)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1A: Ingenol Mebutate Gel 0.005%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E2">
          <title>Part 1A: Ingenol Mebutate Gel 0.008%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E3">
          <title>Part 1A: Ingenol Mebutate Gel 0.012%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E4">
          <title>Part 1A: Ingenol Mebutate Gel 0.018%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E5">
          <title>Part 1A: Ingenol Mebutate Gel 0.027%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E6">
          <title>Part 1A: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E7">
          <title>Part 1B: Ingenol Mebutate Gel 0.04%</title>
          <description>Administration on full face, once daily 2 days</description>
        </group>
        <group group_id="E8">
          <title>Part 1B: Ingenol Mebutate Gel 0.06%</title>
          <description>Administration on full face, once daily 3 days</description>
        </group>
        <group group_id="E9">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 3 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
        <group group_id="E10">
          <title>Part 2: Ingenol Mebutate Gel 0.018% for 2 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
        <group group_id="E11">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 3 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
        <group group_id="E12">
          <title>Part 2: Ingenol Mebutate Gel 0.027% for 2 Days</title>
          <description>Administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
        <group group_id="E13">
          <title>Part 2: Vehicle Gel (Placebo) for 3 Days</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 3 consecutive days</description>
        </group>
        <group group_id="E14">
          <title>Part 2: Vehicle Gel (Placebo) for 2 Days</title>
          <description>Vehicle gel administration on full face, full balding scalp, or approximately 250 cmÂ² on the chest, once daily for 2 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="58" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="59" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="60" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="58" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="56" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="56" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="60" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="57" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Application site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Application site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Appilcation site dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngititis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>upper airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

